← Feed

u/Correct_Proposal_409

2 theses · first seen Sep 4, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$GANXr/pennystocksStock Infobullish
u/Correct_Proposal_409 · 271d ago1 prior · awaiting results

$GANX- CEO interview just came out-- dispels any misconceptions

CEO interview reveals strong biomarker data (GluSph) showing disease modification in Parkinson's treatment with multiple downstream improvements (mitochondrial dysfunction, lysosomal, A-syn aggregation). Author views yesterday's sell-off as an overreaction and believes this is a disease-modifying drug with potential to be the first of its kind, making it an attractive buy at current discount.

Now $1.71as of Sep 15, 4:30 PM ET
original post →
$GANXr/pennystocksGeneral Discussionbullish
u/Correct_Proposal_409 · 279d ago1 prior · awaiting results

$GANX — The Most Asymmetric Setup I’ve Ever Seen (And the Clock Is Ticking)

Gain Therapeutics' GT-02287 shows unprecedented potential as the first disease-modifying drug for Parkinson's, with consistent positive data at every stage (preclinical through phase 1b), no safety issues, and CEO confidence telegraphing imminent data readout within days. Even worst-case scenario (efficacy limited to GBA1 subgroup) de-risks the investment, with realistic 100%+ overnight upside on biomarker confirmation and multi-billion-dollar upside potential from a ~$250M market cap.

Now $1.71as of Sep 15, 4:30 PM ET
original post →

End of results.